YUNNAN BAIYAO(SZ:000538)2024-07-02 10:09Group 1: Business Strategy and Growth - The pharmaceutical business group aims to lead in the injury sector, expand its market presence, and establish a comprehensive operation in the Sanqi industry [2] - The group will deepen academic research and collaborate with various institutions to enhance existing products and explore potential new products [2] - The focus will also be on upstream supply and production coordination to achieve smart manufacturing and cost reduction [2] Group 2: Health Products Performance - The health products business group achieved a revenue of 6.422 billion CNY in 2023, marking a year-on-year growth of 6.50% [3] - Yunnan Baiyao toothpaste holds a 24.60% market share in the domestic market, maintaining its leading position [4] - The health products group recorded significant online sales during the "Double 11" shopping festival, with the flagship store surpassing 100 million CNY in sales for the first time [4] - The anti-hair loss product line, Yangyuanqing, saw a revenue increase of 36%, exceeding 300 million CNY [4] Group 3: Dividend Policy - Yunnan Baiyao's 2023 dividend plan includes a payout of 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which represents 90.53% of the net profit attributable to shareholders [6] - The company has consistently paid dividends for 31 years since its listing, with cumulative cash dividends exceeding 24.4 billion CNY [6] Group 4: R&D Progress in Nuclear Medicine - In 2023, the company made significant advancements in its nuclear medicine pipeline, receiving approval for clinical trials of the INR101 injection [7] - The INR102 project for prostate cancer treatment has completed preliminary studies and initiated pharmaceutical research [7]